Pharmaceutical Executive December 2017

December 2017 | Volume 37, Issue 12
Pharmaceutical Executive December 2017
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive December 2017 issue in an interactive PDF format.
From the Editor
FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.
Pharm Exec details the latest approaches to combating disease and health crises on a global scale—including industry perspectives from those involved on the front lines.
Amid a widening net of health threats worldwide, alliances forged in research and response may be more critical than ever to stem the tide.
Groundbreaking treatment approaches call for innovative commercialization strategies.
How Ruud Dobber is steering AstraZeneca’s US course as it navigates the complexities of a fast-evolving therapeutic market.
Figuring out the right formula to address global health—for the better.
In 2017, patients gained access to the first gene therapies and more orphan and breakthrough drugs.
New action plan urges tighter alignment of public health policy with the development of targeted therapies.
Special Sponsored Section
By Pharmaceutical Executive Editors
Despite having the tenth-largest pharma market in the world and being the birthplace of medical breakthroughs, from insulin to stem cells, Canada seems to be punching below its weight when it comes to health innovation. There are signs, however, that things may be changing as the nation looks to bulk back up.
lorem ipsum